Slate Bio Launches with Seed Financing to Develop Next Generation IL-2 Therapies
Slate Bio Launches with Seed Financing to Develop Next Generation IL-2 Therapies Financing will support development of novel IL-2 treatments for various diseases CHARLOTTESVILLE, Va., Jan. 19, 2021 /PRNewswire/ -- Slate Bio, Inc., announced today the closing of a $1.75 million venture financing. Epidarex Capital led the investment round with participation from the UVA Licensing & Ventures Group Seed Fund, Center for Innovative Technologys GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc.,...
Source: finanznachrichten.de